Cargando…

A combination of extracellular matrix‐ and interferon‐associated signatures identifies high‐grade breast cancers with poor prognosis

Breast cancer (BC) is a heterogeneous disease in which the tumor microenvironment (TME) seems to impact the clinical outcome. Here, we investigated whether a combination of gene expression signatures relating to both the structural and immune TME aspects can help predict prognosis in women with high...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lecchi, Mara, Verderio, Paolo, Cappelletti, Vera, De Santis, Francesca, Paolini, Biagio, Monica, Melissa, Sangaletti, Sabina, Pupa, Serenella Maria, Iorio, Marilena Valeria, Bianchi, Giulia, Gennaro, Massimiliano, Fucà, Giovanni, De Braud, Filippo, Tagliabue, Elda, Di Nicola, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096783/ https://www.ncbi.nlm.nih.gov/pubmed/33523584 http://dx.doi.org/10.1002/1878-0261.12912

Ejemplares similares

Inhibition of the Wnt Signalling Pathway: An Avenue to Control Breast Cancer Aggressiveness
por: Castagnoli, Lorenzo, et al.
Publicado: (2020)

ATF3 Reprograms the Bone Marrow Niche in Response to Early Breast Cancer Transformation
por: Perrone, Milena, et al.
Publicado: (2023)

The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers?
por: Castagnoli, Lorenzo, et al.
Publicado: (2019)

Cancer Stem Cells: Devil or Savior—Looking behind the Scenes of Immunotherapy Failure
por: Castagnoli, Lorenzo, et al.
Publicado: (2020)

Circulating miRNAs as Novel Non-Invasive Biomarkers to Aid the Early Diagnosis of Suspicious Breast Lesions for Which Biopsy Is Recommended
por: Giussani, Marta, et al.
Publicado: (2021)

WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer
por: Castagnoli, Lorenzo, et al.
Publicado: (2019)

The landscape of d16HER2 splice variant expression across HER2-positive cancers
por: Volpi, Chiara Costanza, et al.
Publicado: (2019)

Author Correction: The landscape of d16HER2 splice variant expression across HER2-positive cancers
por: Volpi, Chiara Costanza, et al.
Publicado: (2020)

Decoding Immune Heterogeneity of Triple Negative Breast Cancer and Its Association with Systemic Inflammation
por: Romero-Cordoba, Sandra, et al.
Publicado: (2019)

Gene signatures of circulating breast cancer cell models are a source of novel molecular determinants of metastasis and improve circulating tumor cell detection in patients
por: Fina, Emanuela, et al.
Publicado: (2022)

Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells
por: Fucà, Giovanni, et al.
Publicado: (2021)

Stromal Activation by Tumor Cells: An in Vitro Study in Breast Cancer
por: Merlino, Giuseppe, et al.
Publicado: (2016)

Intratumor lactate levels reflect HER2 addiction status in HER2‐positive breast cancer
por: Castagnoli, Lorenzo, et al.
Publicado: (2018)

The Emerging Role of the Microbiota in Breast Cancer Progression
por: Bernardo, Giancarla, et al.
Publicado: (2023)

Breast Cancer Drug Resistance: Overcoming the Challenge by Capitalizing on MicroRNA and Tumor Microenvironment Interplay
por: Cosentino, Giulia, et al.
Publicado: (2021)

Worldwide SARS-CoV-2 haplotype distribution in early pandemic
por: Cairo, Andrea, et al.
Publicado: (2022)

Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit
por: Triulzi, Tiziana, et al.
Publicado: (2018)

Infrared Spectroscopic Imaging Visualizes a Prognostic Extracellular Matrix-Related Signature in Breast Cancer
por: Tiwari, Saumya, et al.
Publicado: (2020)

Neutrophil extracellular traps arm DC vaccination against NPM-mutant myeloproliferation
por: Tripodo, Claudio, et al.
Publicado: (2022)

Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment
por: Rybinska, Ilona, et al.
Publicado: (2020)

Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients
por: Ligorio, Francesca, et al.
Publicado: (2021)

Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world
por: Di Cosimo, Serena, et al.
Publicado: (2022)

Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies
por: Cona, Maria Silvia, et al.
Publicado: (2019)

3Rs Principle and Legislative Decrees to Achieve High Standard of Animal Research
por: Verderio, Paolo, et al.
Publicado: (2023)

Identification of Relevant Conformational Epitopes on the HER2 Oncoprotein by Using Large Fragment Phage Display (LFPD)
por: Gabrielli, Federico, et al.
Publicado: (2013)

Increased Sensitivity to Chemotherapy Induced by CpG-ODN Treatment Is Mediated by microRNA Modulation
por: De Cecco, Loris, et al.
Publicado: (2013)

Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer
por: Castagnoli, Lorenzo, et al.
Publicado: (2023)

MiR-302b as a Combinatorial Therapeutic Approach to Improve Cisplatin Chemotherapy Efficacy in Human Triple-Negative Breast Cancer
por: Cataldo, Alessandra, et al.
Publicado: (2020)

Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer
por: Silvestri, Marco, et al.
Publicado: (2022)

A three-gene signature marks the time to locoregional recurrence in luminal-like breast cancer
por: Chiodoni, C., et al.
Publicado: (2023)

The Role of MicroRNAs in HER2-Positive Breast Cancer: Where We Are and Future Prospective
por: Fogazzi, Valentina, et al.
Publicado: (2022)

Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications
por: Ligorio, Francesca, et al.
Publicado: (2022)

The Human Splice Variant Δ16HER2 Induces Rapid Tumor Onset in a Reporter Transgenic Mouse
por: Marchini, Cristina, et al.
Publicado: (2011)

miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response
por: Cataldo, Alessandra, et al.
Publicado: (2015)

Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy
por: Fucà, G., et al.
Publicado: (2021)

The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab
por: Ligorio, Francesca, et al.
Publicado: (2021)

Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin
por: Zattarin, Emma, et al.
Publicado: (2022)

A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancer
por: Reduzzi, Carolina, et al.
Publicado: (2019)

Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center
por: Fucà, Giovanni, et al.
Publicado: (2022)

HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response
por: Palladini, Arianna, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qoip3tptmbk8dvm1l867sn96c3